On March 19, 2018 OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED), a clinical-stage biopharmaceutical company focused on discovering and developing novel anti-cancer therapeutics, reported the appointment of Dr. John Lewicki as President and Chief Executive Officer of OncoMed, effective immediately. Dr. Lewicki was also appointed to the company’s Board of Directors (Press release, OncoMed, MAR 19, 2018, View Source [SID1234524877]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"John has been a key member of the OncoMed leadership team since the formation of the company, and he has guided our science to the discovery and development of all of our therapeutic candidates," said Perry Karsen, Executive Chairman of OncoMed’s Board of Directors. "The OncoMed Board of Directors and I are fully confident that John’s leadership as President and Chief Executive Officer will help ensure the company maximizes the value of our therapeutic candidates for cancer patients and our shareholders. We look forward to working closely with John and the entire OncoMed team to have a positive impact on cancer patients."

"I am honored to now serve as OncoMed’s President, Chief Executive Officer and a member of the Board, and to be given the opportunity to lead the company at this pivotal time as we advance our lead therapeutic candidates, anti-TIGIT, GITRL-Fc, and navicixizumab, through clinical development," said Dr. Lewicki. "I am very excited to continue working with my OncoMed colleagues in my new role as we strive to discover and develop cancer therapeutics for patients in need, while creating value for our shareholders."

Most recently, Dr. Lewicki was named the company’s President in January 2018. Dr. Lewicki joined OncoMed in 2004 as the company’s Senior Vice President of Research and Development before subsequently assuming additional leadership roles within Research and Development. Dr. Lewicki was named the company’s Executive Vice President and Chief Scientific Officer in 2009 and then became Executive Vice President, Research and Development in 2016. Earlier in his career, Dr. Lewicki served in various capacities at Scios, Inc., where as Vice President of Research, he managed the company’s organization across diverse therapeutic areas. Among his achievements while at Scios was the co-discovery of human B-type natriuretic peptide and its development as an FDA-approved treatment for acute congestive heart failure.

On March 19, 2018 Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a leader in the development of restorative cell therapies that may offer rapid-onset pain relief and restored function, reported that Adam Gridley, Chief Executive Officer of Histogenics, will be presenting a corporate overview at Needham & Company’s 17th Annual Healthcare Conference on, March 28, 2018 at 11:00 AM EDT at the Westin Grand Central Hotel in New York, NY (Press release, Histogenics, MAR 19, 2018, View Source;p=RssLanding&cat=news&id=2338678 [SID1234524888]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To access a live audio webcast of the presentations on the "Investor Relations" page of the Histogenics website, please click here. The webcasts will be available for approximately 45 days following the respective conferences.

On March 19, 2018 Oncoceutics, Inc. reported that multiple abstracts from the company and its commercial and academic collaborators will be presented at the 2018 annual meeting of the American Association of Cancer Research (AACR) (Free AACR Whitepaper) in Chicago, Illinois, on April 14th to April 18th (Press release, Oncoceutics, MAR 19, 2018, View Source [SID1234558371]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

These abstracts highlight the unique way that ONC201 engages the dopamine receptor, leading to downstream direct anti-tumor and immune oncology effects, which are especially pronounced in tumors with dopamine pathway dysregulation. These tumors include H3 K27M mutant high grade gliomas and other cancers, where ONC201 is now in advanced clinical trials.

Additionally, the abstracts showcase the continued preclinical advancement of other members of the imipridone family. ONC212 will be featured in an oral presentation highlighting its ability to treat aggressive leukemias as a single agent, and effectively synergize with other anti-leukemic agents, specifically BCL-2 inhibitors, due to its unique GPCR target. ONC206 demonstrates parallel characteristics with ONC201, while also being differentiated by a unique binding profile.

The abstracts are listed below and categorized by topic: ONC201 clinical translation; ONC201 preclinical single agent and combinatorial activity; and analogs (ONC206 and ONC212). All poster presentations will be in McCormick Place South, Exhibit Hall A, and the oral presentation of ONC212 will take place in Room S102 – McCormick Place South (Level 1) at the times described below.

ONC201 Clinical Translation:

Selective targeting of dopamine receptor dysregulation in high grade gliomas with imipridone ONC201
April 17, 2018, 8:00 AM

ONC201 induction of apoptosis in hPheo1 cell line supports use of this oral agent in ongoing phase 2 clinical trial against neuroendocrine tumors
April 17, 2018, 1:00 PM

Clinical immunostimulatory activity of imipridone ONC201, a selective DRD2 antagonist, in advanced solid tumor patients
April 18, 2018, 8:00 AM

ONC201 Preclinical Single Agent and Combinatorial Activity

Treatment and signaling contexts for the application of the imipridone ONC201 to prostate cancer cells
April 15, 2018, 1:00 PM

LB-082. ONC201 sensitizes resistant breast cancer cells to TRAIL through death receptor 5 upregulation

April 16, 2018, 8:00 AM – 12:00 PM

Synergistic antitumor effect of ONC201 in combination with radiation therapy
April 16, 2018, 1:00 PM

Combination ONC201 and radiation therapy in the treatment of breast cancer
April 16, 2018, 1:00 PM

Analogs (ONC206 and ONC212):

Receptor pharmacology and anti-cancer activity of selective DRD2/3 antagonist imipridone ONC206
April 17, 2018, 1:00 PM

The novel imipridone ONC212 highly synergizes with the BCL-2 inhibitor ABT-199 in AML and activates orphan receptor GPR132
April 17, 2018, 3:35 PM – Oral Presentation

Oncolytics Biotech has filed a 20-F – Annual and transition report of foreign private issuers [Sections 13 or 15(d)] with the U.S. Securities and Exchange Commission (Filing, 20-F, Oncolytics Biotech, 2018, MAR 19, 2018, View Source [SID1234524879]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On March 19, 2018 Molecular Templates, Inc., (Nasdaq:MTEM) a clinical stage biopharmaceutical company focused on the discovery and development of Engineered Toxin Bodies (ETBs), a new class of targeted biologic therapies that possess unique mechanisms of action in oncology, reported that its management will provide a corporate overview at the Oppenheimer 28th Annual Healthcare Conference, taking place March 20-21 at the Westin New York Grand Central hotel in New York City (Press release, Molecular Templates, MAR 19, 2018, View Source [SID1234524890]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!